NPPB and hydrops fetalis: The benefits were even greater among participants with NT-proBNP < 4000 pg/mL (adjusted HR: 0.77; 95% CI: 0.68–0.88 for primary endpoint; adjusted HR: 0.75; 95% CI: 0.60–0.94 for cardiovascular death; adjusted HR: 0.78; 95% CI: 0.67–0.90 for HF-related hospitalizations).